The Society for Clinical Research Sites (SCRS) announced that StudyKIK has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides an opportunity for sponsors, CROs, and solution providers to engage with SCRS and its members. Becoming a GIP demonstrates StudyKIK’s commitment to clinical research sites, their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions in the marketplace.
"StudyKIK has believed in SCRS and the vision Christine Pierre founded the organization on, which is to be the unified voice for all research sites, since its inception," said the company's president and co-founder, Matt Miller. "We started StudyKIK with the same vision by building tools to empower sites to succeed in patient recruitment. Becoming an SCRS Global Impact Partner strengthens our commitment to supporting research sites and connecting patients to clinical trials."
“By joining SCRS as a GIP, StudyKIK has demonstrated their commitment to a strong and unified site community,” said SCRS president Casey Orvin. “StudyKIK has had a consistent presence at SCRS’ Site Solutions Summits throughout the years, and we are looking forward to expanding our engagement with the company through the GIP program.”
For more information, visit www.MySCRS.org
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.